Growth hormone excess and the effect of octreotide in cats with diabetes mellitus

Slingerland, L.I.; Voorhout, George; Rijnberk, A.; Kooistra, Hans S.

doi:10.1016/j.domaniend.2008.07.004

Cited by 31 publications

(26 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of treated cats, however, is small, and no systematic evaluations of dose-responses have been performed. Two of the five acromegalic cats showed a clear-cut decrease in GH concentrations, whereas the decrease in the other three cats was small (Slingerland et al, 2008). [semel in die; once a day], increased to 10 mg s.i.d.…”

Section: Catsmentioning

confidence: 99%

Disorders of Growth Hormone

Reusch¹

2015

Canine and Feline Endocrinology

View full text Add to dashboard Cite

Section: Catsmentioning

confidence: 99%

Disorders of Growth Hormone

Reusch¹

2015

Canine and Feline Endocrinology

View full text Add to dashboard Cite

“…9 Intravenously administered octreotide decreases serum GH concentration in a minority of affected cats, but clinical effects were not reported. 10 These results raise questions, such as: do somatotrophinomas in cats express somatostatin receptors consistently or is the configuration of their SSTRs different from those found in somatotrophinomas of humans?…”

mentioning

confidence: 99%

Pasireotide for the Medical Management of Feline Hypersomatotropism

Scudder

Gostelow

Forcada

et al. 2015

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundFeline hypersomatotropism (HST) is a cause of diabetes mellitus in cats. Pasireotide is a novel multireceptor ligand somatostatin analog that improves biochemical control of humans with HST.Hypothesis/ObjectivesPasireotide improves biochemical control of HST and diabetes mellitus in cats.AnimalsHypersomatotropism was diagnosed in diabetic cats with serum insulin‐like growth factor‐1 (IGF‐1) concentration >1,000 ng/mL by radioimmunoassay and pituitary enlargement.MethodsInsulin‐like growth factor 1 was measured and glycemic control assessed using a 12‐hour blood glucose curve on days 1 and 5. On days 2, 3, and 4, cats received 0.03 mg/kg pasireotide SC q12h. IGF‐1, insulin dose, and estimated insulin sensitivity (product of the area under the blood glucose curve [BGC] and insulin dose) were compared pre‐ and post treatment. Paired t‐tests or Wilcoxon signed rank tests were employed for comparison where appropriate; a linear mixed model was created to compare BGC results.ResultsInsulin‐like growth factor 1 decreased in all 12 cats that completed the study (median [range] day 1: 2,000 ng/mL [1,051–2,000] and day 5: 1,105 ng/mL [380–1,727], P = .002, Wilcoxon signed rank test). Insulin dose was lower on day 5 than on day 1 (mean reduction 1.3 [0–2.7] units/kg/injection, P = .003, paired t‐test). The product of insulin dose and area under the BGC was lower on day 5 than day 1 (difference of means: 1,912; SD, 1523; u × mg/dL × hours, P = .001; paired t‐test). No clinically relevant adverse effects were encountered.ConclusionsShort‐acting pasireotide rapidly decreased IGF‐1 in cats with HST and insulin‐dependent diabetes. The decrease in IGF‐1 was associated with increased insulin sensitivity.

show abstract

“…Similar results were obtained in a population of cats with acromegaly, in which 5 µg/kg somatostatin was able to decrease but not normalise the plasma GH concentrations. 12 …”

Section: Discussionmentioning

confidence: 99%

Acromegaly in a non-diabetic cat

Fracassi

Salsi

Sammartano

et al. 2016

Journal of Feline Medicine and Surgery Open Reports

View full text Add to dashboard Cite

Case summaryA 14-year-old, neutered male European shorthair cat was evaluated for a routine health check. The owner did not report any clinical signs except for respiratory stridor. On physical examination the main findings were broad facial features and increased interdental spaces. On haematology, a mild, non-regenerative anaemia was detected, whereas the serum biochemistry profile and urinalysis were unremarkable. The serum glucose concentration was within the reference interval. Serum insulin-like growth factor-1 concentration was markedly elevated (>1600 ng/ml). The basal serum growth hormone concentration was elevated and decreased only mildly after somatostatin administration. Basal serum insulin concentration was high, and the insulin concentration increased considerably after glucose loading, consistent with insulin resistance. CT scanning of the skull showed an enlarged pituitary gland and increased skull bone thickness. The final diagnosis was acromegaly.Relevance and novel informationThese findings demonstrate that acromegaly should be pursued and suspected in cats other than those with diabetes mellitus.

show abstract

Growth hormone excess and the effect of octreotide in cats with diabetes mellitus

Cited by 31 publications

References 45 publications

Disorders of Growth Hormone

Disorders of Growth Hormone

Pasireotide for the Medical Management of Feline Hypersomatotropism

Acromegaly in a non-diabetic cat

Contact Info

Product

Resources

About